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1. Introduction
Haemostasis is a complex balance between thrombus formation and fibrinolysis. Research into
bleeding and thrombotic conditions has lead over many years to a detailed knowledge of the
role of the components of coagulation, and subsequently many clinical applications have been
developed for the testing of platelets, clotting factors and coagulation inhibitors. However, the
same cannot be said for the components of fibrinolysis. Fibrinolytic research over the last 30
years has not resulted in the translation of basic science into routine clinical tests of fibrinolytic
factors [1, 2], except for D-dimer assays, which are an indirect marker of both thrombosis and
fibrinolysis. This has occurred partly due to the difficulties with individual fibrinolytic factor
assays, but also due to the inherent limitation of using a single factor assessment to quantify
the complex and dynamic process of fibrinolysis.
An ideal assay that could provide an overall or ‘global’ assessment of haemostasis would take
into account the interactions between the proteins of the coagulation and fibrinolytic pathways,
blood cellular components and the vessel wall. Such an assay does not currently exist, but
refinements of old techniques with updated technology and the development of new global
assays have brought improvements in this regard. The ability to assess fibrinolysis is a major
benefit of some of these global assays, and has led renewed interest in this field.
Potential clinical applications
There are multiple potential clinical situations in which the ability to detect hypo- or hyperfi‐
brinolysis could in theory be useful. Hypofibrinolysis is a risk factor for thrombosis. Venous
thromboembolism (VTE) is a common condition, with an incidence of approximately 1 in 1000
adults [3]. A potential benefit of detecting a fibrinolytic defect would be to identify individuals
at higher risk of a first event, which could lead to different management strategies particularly
in clinical scenarios such as pregnancy and the peri-operative period where the risk is already
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known to be higher. This is relevant because currently only approximately one quarter of
patients have a detectable inherited or acquired thrombophilia on testing, and 20% of patients
have no cause at all found for their first VTE [3-5]. In addition, recurrent VTE events occur in
approximately 20-30% of patients within 5 years [4, 6], and identification of hypofibrinolysis
as a risk factor might be useful in informing the duration of anticoagulation. Hypofibrinolysis
may also be important in arterial thrombosis such as myocardial infarction, and the ability to
detect patients who are at increased risk of infarction or stent occlusion due impaired clot lysis
would be an important clinical application [7].
Hyperfibrinolysis can result in an increased bleeding risk during surgery and invasive
procedures. As it is associated with increased morbidity and mortality, identifying hyperfi‐
brinolysis is a key aim for fibrinolytic assays [8]. Particularly in major procedures such as liver
transplant, cardiac valve repair or revascularisation surgery, challenges to the haemostatic
system are complex and continuously evolving, and the ability to rapidly detect hyperfibri‐
nolysis in these patients has lead to an improvement in their care [8-10]. Recently, attention
has turned to the need for measuring fibrinolysis in trauma patients since the publication of a
large multinational study revealed improvements in survival with the early administration of
an anti-fibrinolytic drug [11]. Increased fibrinolysis can also be detected in some patients with
inherited bleeding conditions such as haemophilia A, indicating that anti-fibrinolytics may
also benefit these patients. Finally, disseminated intravascular coagulation (DIC) is a syndrome
with abnormal activation of the both coagulation and fibrinolytic systems. Identifying
hyperfibrinolysis in suspected cases could assist in the diagnosis of DIC, which otherwise
requires complex scoring systems [12].
In this chapter we review assays of the individual factors of the fibrinolytic system and global
tests which provide an overall assessment of the fibrinolysis. In each section we will outline
the assay itself and its strengths and weakness, before reviewing the literature regarding its
use and current or future clinical applications.
2. Fibrinolytic factors
2.1. Plasmin and α2-plasmin inhibitor
The proteolytic enzyme plasmin is the main mechanism through which intravascular fibrin
thrombi are degraded. It circulates as its inactive form, plasminogen, at a plasma concentration
of approximately 2 μmol/L and is activated intravascularly by tissue plasminogen activator
(tPA) [13, 14]. The localization to intravascular thrombi and formation of the active protease
occurs more readily after both plasminogen and tPA are bound to fibrin. Any free plasmin is
bound by its primary physiological inhibitor, α2-plasmin inhibitor. This circulates at levels of
approximately 1 μmol/L in normal plasma (table 1), and neutralizes plasmin so rapidly that
the active enzyme is undetectable in plasma. Assays have therefore been aimed at measuring
plasminogen, α2-plasmin inhibitor or the plasmin-α2-plasmin inhibitor (PAP) complex.
Plasminogen activity has been most frequently measured using a functional chromogenic
assay, but antigenic assays are also available. In the functional assay, an extrinsic activator,
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streptokinase, which acts on free as well as bound plasminogen, is added to a patient’s plasma
to convert all of the plasminogen to plasmin, which then acts on a chromogenic substrate [14,
15]. Several commercial kits are available. Where low activity levels are found, plasminogen
antigen concentrations can be measured by enzyme-linked immunosorbent assays (ELISA) or
nephelometry to distinguish between lack of plasminogen (type 1 deficiency) and dysplasmi‐
nogenaemia (type 2 defects) [15, 16]. PAP complexes have been assayed by ELISA kits [17,
18], and chromogenic assays have also been used to detect unbound α2-plasmin inhibitor
activity [19].
Plasma concentration
Site of Synthesis Plasma half life(approximate)(µg/ml) (mol)
Plasminogen 200 2 µmol/L Liver 1.8 – 2.7 days
Plasmin Undetectable - - Very Brief
α2-plasmin inhibitor 70 1 µmol/L Liver 12 hours
tPA 0.005 70 ρmol/L Vascular endothelium 5 minutes
PAI-1 0.02 400 ρmol/L Vascular endothelium, Liver,Adipocytes 2 hours
TAFI 5 75 nmol/L Liver, Megakaryocytes 10 minutes
Table 1. Synthesis, plasma concentration and half life of fibrinolytic factors [13, 20, 21]
Congenital deficiency and venous thrombosis
The clinical consequences of low plasminogen levels have been studied in patients with
congenital deficiency. The prevalence of plasminogen deficiency in the general population has
been estimated at 0.3% in a large Scottish cohort of blood donors [22], and 4.3% in a Japanese
study [23]. The higher prevalence in the latter population is due the high frequency of a specific
plasminogen gene mutation (Ala6012Thr) in East Asian populations causing type 2 deficiency,
with similar rates of type 1 disease in each study. Surprisingly, no definite relationship between
either type of deficiency and arterial or venous thrombosis has been found [15, 16, 22, 23]. A
modestly increased risk suggested by the combined findings of family studies was not
statistically significant [15], and has not been confirmed in larger population-based research
[22, 23]. Even in severe homozygous plasminogen deficiency there is no excess of thrombotic
events; instead the main clinical phenotype is an accumulation of ‘ligneous’ fibrin-rich,
pseudomembranous lesions in the conjunctiva and less commonly in other mucosal mem‐
branes [16]. The reason for a lack of thrombotic phenotype is unclear. It may be that residual
plasminogen activity in these homozygous patients (the majority display between 4% and 51%
activity) is enough to prevent the small vessel thrombosis seen in mouse gene knock-out
models where there is no detectable plasminogen [24, 25], or that alternative fibrinolytic
proteases released from neutrophils degrade fibrin [26].
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Despite the evidence from congenital deficiency states, a small number of studies have
investigated plasminogen or α2-plasmin inhibitor levels as a risk factor for venous thrombosis
in non-deficient patients. A large case-control study of 770 patients and 743 controls (the MEGA
study) found that modest correlations between thrombosis and plasminogen or α2-plasmin
inhibitor were lost after adjustment for markers of inflammation and Body Mass Index [27],
and the prospective cohort LITE study found no relationship with PAP complexes [18]. A small
series of patients with Budd-Chiari syndrome were found to have a slight but statistically
significant decrease in plasmin inhibitor levels [28].
Arterial thrombosis
Some large cohort and case-control studies have investigated an association between fibrinolyt‐
ic proteins and myocardial infarction (MI). High plasminogen levels have surprisingly been
consistently associated with a modest elevated risk of myocardial infarction [29-31]. However
only one of these studies adjusted for inflammation or smoking [31], which along with elevated
cholesterol  are  potential  confounding factors,  and the  association with  MI was  lost.  An
alternative explanation may be that  plasmin is  known to contribute to the instability  of
atherosclerotic plaques by activating matrix metalloproteinases [32]. Alpha-2-plasmin inhibitor
was also investigated, no association with MI being found in the prospective cohort ECAT study
[29], and a slight positive correlation in the retrospective case-control SMILE study [31].
Hyperfibrinolytic states
Raised levels of PAP complexes and decreased levels of α2-plasmin inhibitor have been
described in hyperfibrinolytic states, such as acute coagulopathy of trauma [reviewed in 17,
33], disseminated intravascular coagulation (DIC) [34] and the coagulopathy of acute pro‐
myelocytic leukaemia [reviewed in 35]. However, no clinical applications have been estab‐
lished, for example as a risk factor of severity.
Rare congenital α2-plasmin inhibitor deficiency has been described [reviewed in 36]. Homo‐
zygous deficiency results in a severe bleeding disorder due to increased fibrinolysis with a
similar phenotype to congenital haemophilia or Factor XIII deficiency. Conventional haemo‐
stasis screening tests are normal, and a functional α2-plasmin inhibitor assay is required to
make the diagnosis.
Summary
In summary, research has not resulted in any clinical applications of assays of plasminogen,
α2-plasmin inhibitor or PAP complexes in the investigation of fibrinolytic activity despite their
central role, perhaps because they circulate at relatively high concentrations and are generally
not rate-limiting factors [13]. In rare cases of congenital deficiency of these proteins, functional
assays can be used to make the diagnosis.
2.2. Tissue Plasminogen Activator (tPA) and Plasminogen Activator Inhibitor-1 (PAI-1)
Both tPA and PAI-1 have been investigated as markers of fibrinolytic activity. After stimula‐
tion, tPA is released locally from endothelial cells and activated platelets, and binds to the
Fibrinolysis and Thrombolysis128
fibrin surface of the developing thrombus where it catalyses the formation of plasmin. Once
bound, it is protected from its principle inhibitor PAI-1, which circulates in plasma and is also
secreted by platelets [13, 37]. Free tPA has a plasma half life of approximately 5 minutes due
to the action of PAI-1 and simultaneous clearance by the liver [13]. Therefore resting levels of
unbound active tPA in plasma are very low and may be measured by ELISAs that detect both
the active form and the tPA – PAI-1 complex. PAI-1 levels have been investigated using
functional assays and various ELISAs, which utilise a range of monoclonal antibodies with
varying sensitivities for unbound PAI-1 and the tPA-PAI-1 complex [38].
There are several issues that complicate the results of these assays. The first is that measuring
resting plasma levels of tPA detects mainly inactive complexes with PAI-1, and so raised levels
of tPA antigen may indicate inhibited fibrinolysis rather than increased fibrinolytic potential
[2]. An inverse relationship between antigen and fibrinolytic activity has even been found [39,
40]. To overcome this, some investigators have measured acute tPA release following stimu‐
lation such as prolonged venous occlusion by a tourniquet. However, it is not clear whether
this is a better reflection of the physiological situation [7]. In addition, plasma levels of PAI-1
do not reflect its true contribution in inhibiting fibrinolysis as the majority of PAI-1 is released
at the site of thrombus by activated platelets [37, 41] and plasma and platelet pools of PAI-1
vary independently of each other [42].
Levels of PAI-1 and tPA are affected by other factors. PAI-1 in particular has many non-
fibrinolytic functions, and may be raised in diabetes mellitus and insulin resistance [reviewed
in 2]. Both tPA and PAI-1 are acute phase reactants and elevated with raised lipids and
pregnancy [29, 31]. Furthermore, there is marked diurnal variation in their levels, being higher
in the morning [43].
Arterial and venous thrombosis
The association between tPA and PAI-1 antigen levels with arterial disease and thrombosis
has been investigated in multiple large studies with conflicting results, described in two recent
reviews [2, 7]. Although some studies have found increased tPA and PAI-1 levels to be
associated with an increased risk of arterial disease or recurrent events [reviewed in 44, 45],
some major publications including the Framingham study have reported no association [30,
46], and in two studies even a trend to decreased risk was found in subjects with elevated PAI-1
[47, 48]. The use of assays measuring tPA release has not resulted in any clarity, increased
levels being associated with major atherothrombotic events in one study [49] and the inverse
in another [29]. These confusing results may be partly accounted for by confounding factors
demonstrated by studies that have adjusted for a range other risk factors such as diabetes,
cholesterol, obesity, and inflammation. In the ECAT, SMILE and Young Finn studies, apparent
associations between PAI-1 or tPA and arterial risk were lost when other these other factors
were included in the analyses [29, 31, 50].
The data on tPA and PAI-1 as risk factors for venous thrombosis has similarly failed to find
any clinically useful associations [reviewed in 1, 2]. Some prospective studies have found no
differences in antigen levels between patients who suffered thrombosis and controls [18, 51,
52], whereas a recent large retrospective study has found PAI-1 to be a risk factor for first
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venous thrombosis and to be the most important determinant in Clot Lysis Time (CLT), a global
test for hypofibrinolysis described later in this chapter [27].
Hyperfibrinolytic states
PAI-1 and tPA levels have been investigated in various hyperfibrinolytic states. PAI-1 has been
suggested as a potential therapeutic target in DIC since raised levels correlate with multi-organ
failure and outcome [53], whereas in acute traumatic coagulopathy, no association between
PAI-1 and severity of injury has been found [17]. In liver cirrhosis, raised tPA levels are
proportional to the severity of cirrhosis and risk of variceal bleeding, and may be mediated by
a relative deficiency of PAI-1 [discussed in 54].
Summary
Despite a large amount of data on tPA and PAI-1 levels in the literature, no current clinical
applications have emerged. The methodological problems and confounding factors discussed
above have played a major role in the lack of consistent clinical correlations with disease and
outcome.
2.3. Thrombin activatable fibrinolysis inhibitor (TAFI)
TAFI circulates in plasma as a proenzyme and is converted into its active form TAFIa by
thrombin or the thrombin-thrombomodulin complex. It then removes specific lysine or
arginine residues from partially degraded fibrin, thereby preventing tPA and plasminogen
binding which is required for efficient activation of fibrinolysis [13]. It is unstable in plasma,
spontaneously degrading to a latent form (TAFIai) with a half life of approximately 10 mins
(Table 1).
TAFI can be quantified by ELISA or functional assay. The ELISAs have the advantage of being
easy to perform. However there are important differences in the specificities of the antibodies
used; they variably measure total antigen, be specific to certain TAFI genotypes, or measure
activated TAFI only by being specific for the TAFIa-TAFIai complex [2, 7, 21]. The functional
assays measure the ability to cleave residues from small synthetic substrates and have the
advantage of measuring all active TAFI, although there may be interference by other carbox‐
ypeptidases in plasma. A practical disadvantage is that they are affected by the variable
thermal instability of TAFIa, so samples have to be placed on ice immediately and centrifuged
at 40C, and they also must be collected in tubes containing thrombin and plasmin inhibitors to
prevent in-vitro activation [21].
Venous and arterial thrombosis
Raised TAFI levels appear to be consistently associated with venous thromboembolism. In a
large case-control study, the Leiden Thrombophilia Study (LETS), TAFI antigen levels above
the 90th percentile of controls were found to be associated with an almost two-fold increased
risk of first deep vein thrombosis [55], a finding replicated in a smaller case control study using
an ELISA specifically designed to be insensitive to different polymorphisms of TAFI [56]. There
is some evidence that recurrent venous thromboemboli may be predicted by high TAFI levels;
a prospective study of 600 patients with unprovoked venous thrombosis found a two-fold risk
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of recurrence if their TAFI levels were above the 75th percentile [57]. Disappointingly, this
association could not be confirmed in a follow-up to the LETS study, although this may be
because patients with provoked thrombotic events were included [58].
The association between TAFI levels and arterial disease are unclear. Some studies have found
a link between high TAFIa (but not total TAFI antigen) and coronary artery disease or
myocardial infarction [59, 60], but others have found no association [61, 62] and some have
found low total TAFI antigen levels to be associated with increased risk [63, 64].
Other diseases
Associations have been investigated between TAFI and a variety of other disease states such
as renal failure, hepatic disease, endocrine disorders, cancer, DIC and pregnancy complica‐
tions [reviewed in 21] without useful clinical applications arising. One recent study has shown
an interesting correlation that suggests the variable bleeding phenotype seen in severe
Haemophilia A may be associated with TAFI activation levels [65].
Summary
Once again, the problems with TAFI assays and the lack of consistent significant associations
with disease mean that there are no current clinical applications. However the possible
association of raised TAFI with recurrent unprovoked venous thrombosis warrants further
study.
2.4. Other factors affecting fibrinolysis
Lipoprotein(a) or Lp(a) is a homologue of plasminogen that circulates in plasma and is able to
inhibit t-PA mediated plasminogen activation at the fibrin surface [7]. It has been investigated
as a risk factor for arterial thrombosis in several prospective studies, and a consistent but weak
association has been seen with cardiovascular events in both young and elderly patients
[reviewed in 7]. A meta-analysis of prospective studies over the last 40 years, involving
approximately 127 000 subjects, found that Lp(a) concentrations were an independent risk
factor for both coronary disease and stroke but not clinical outcome. The effect was weak, with
a hazard ratio of just 1.13 [66]. Therefore on an individual patient basis, assays of Lp(a) are
unlikely to be useful.
Annexin A2 receptors on the endothelial cell surface bind both plasminogen and tPA, and
accelerate plasminogen activation 60-fold [13]. Recent publications have shown that autoan‐
tibodies to annexin A2 are associated with thrombosis in patients with antiphospholipid
syndrome [67]. Another interesting finding has been that autoantibodies to annexin A2 occur
in a subset of patients with cerebral sinus thrombosis with or without antiphospholipid
antibodies; testing for anti-annexin antibodies may have a role in establishing aetiology in
these patients whose thrombosis is otherwise often thought to be idiopathic [68].
2.5. D-dimers
D-dimers are a specific cross-linked fibrin degradation product. Their formation depends on
thrombin converting fibrin to fibrinogen and activating factor XIII (FXIIIa), which then cross-
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links the D-domains of adjacent fibrin strands prior to cleavage by plasmin. Thus D-dimers
can be seen as an indirect marker of both coagulation and fibrinolysis, although low levels can
be seen under normal physiological conditions, and raised levels may occur in pregnancy,
advancing age and a wide range of inflammatory and malignant conditions as well as
thrombosis [reviewed in 69]. For these reasons specific, evaluation of the fibrinolytic system
with D-dimer results alone is problematic, and we will only briefly summarise the assays and
their established clinical applications below.
D-dimers can be measured using monoclonal antibodies that have variable specificity for an
antigen found in the FXIIIa cross-linked fragments of fibrin compared to other fibrin degra‐
dation products. Multiple assays have been developed using three techniques: quantitative
ELISAs, whole blood agglutination (qualitative), and latex bead agglutination assays that can
be performed on routine laboratory coagulation analysers and may be quantitative or quali‐
tative [69]. It is important to note that results are not comparable between different assays,
even between those of similar formats. For this reason it is important that clinicians and
researchers are aware of the performance characteristics of the individual assay they are using,
and the clinical setting for which it has been validated [70]. In addition, many of the commonly
used assays may give false positive results due to lipaemia, hyperbilirubinaemia, intravascular
haemolysis or high levels of rheumatoid factor [69], and anticoagulation reduces D-dimer
levels even within 24 hours of commencement [71].
Venous thromboembolism
D-dimers are typically elevated in acute VTE. However, because they are increased in a variety
of other non-thrombotic disorders, raised D-dimers are a sensitive but not specific marker. As
mentioned above, D-dimer assays vary; the latex agglutination and ELISA methods are the
most sensitive (93-96%) but least specific (43-53%) [72], and consequently a ‘negative’ or normal
range result in these has a high negative predictive value. Multiple studies have shown the D-
dimer assay can be successfully combined with clinical probability scoring systems in the
diagnosis of suspected lower extremity DVT or PE [reviewed in 69] and their use has been
recommended in recent guidelines [73]. In patients with a low or moderate pre-test probability
of DVT, a negative D-dimer test of high sensitivity can exclude a DVT without the need for
further investigations. Similar strategies can be used in patients with suspected PE [69], but
not in upper limb venous thrombosis [73], and the test is less useful in the elderly, hospital
inpatients or those with malignancy due to the high prevalence of elevated D-dimers in these
groups reducing assay specificity [74].
There is an increased risk of recurrent VTE in patients with evidence of ongoing activation of
the coagulation and fibrinolytic systems, as indicated by a raised D-dimer after the cessation
of anticoagulant therapy [69, 75]. This may be used to inform treatment decisions regarding
the duration of anticoagulation; a major study (PROLONG) randomised patients to restarting
anticoagulation or observation if their D-dimer was raised a month after treatment had ceased.
The recurrent VTE rate was demonstrated to be significantly less in those who had restarted
anticoagulation [76].
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Disseminated Intravascular Coagulation
DIC can be characterised as a syndrome with uncontrolled activation of the both coagulation
and fibrinolytic systems, and consequently raised D-dimer levels are a sensitive but non-
specific marker [69]. As no single test can establish the diagnosis, D-dimers have been used in
scoring systems to establish the likelihood of DIC and monitor the effect of interventions, such
as the one developed by the International Society on Thrombosis and Haemostasis (ISTH) [12].
3. Global fibrinolytic assays
The difficulties described above in using individual fibrinolytic markers to measure the
fibrinolytic potential of a patient’s plasma has lead to increasing interest in global tests that
provide an overview of the entire process. Below we discuss thromboelastography, and fibrin
generation and lysis assays which have current or potential clinical applications.
3.1. Thromboelastography
Thromboelastography uses viscoelastic changes during coagulation to produce a graphical
representation of the fibrin polymerisation process and subsequent fibrinolysis, and as such
it has the potential to provide a global evaluation of clot initiation, formation and lysis. First
described in 1948 in Germany, two commercial analysers are currently available: the Throm‐
boelastograph or ‘TEG’ (Haemonetics, MA, USA) and the Rotational Thromboelastogram or
‘ROTEM’ (Tem International GmBH, Munich, Germany). Both of these are suitable for use as
‘point of care’ (POC) devices, and this setting is where thromboelastography has developed
its main clinical applications.
The principle of the thromboelastogram is as follows [8, 9]; whole blood is added to an
incubated cup at 37oC, into which a pin is suspended connected to a detector system. As cup
and pin are oscillated relative to each other, the increasing viscosity from the developing fibrin
polymerisation affects the magnitude of the movement of the pin, which is converted by a
mechanical–electrical transducer to a signal which is displayed as a trace (Figure 1a). As
fibrinolysis occurs, the viscosity falls and is also recorded on the trace. As well as the graphical
output, values are calculated for various parameters which include: time until initial fibrin
formation, clot formation time, rate of polymerisation of fibrin, maximum clot firmness, and
clot lysis. Table 2 lists these and the haemostatic variables they are proposed to measure.
Although the TEG and ROTEM are similar in their technologies, there are some important
differences. Firstly, in the TEG, the movement is initiated in the cup and a torsion wire monitors
the changes in the sample, whereas in the ROTEM, the pin moves on a ball bearing and there
is an optical detection system. Some authors claim this modification has led to the ROTEM
being more robust in busy clinical settings such as emergency departments and operating
theatres [78, 79]. The ROTEM system also has an electronic pipette to help standardise the
method. Both systems use proprietary initiators or modifiers of haemostasis, and the TEG can
run two assays in series, whereas the ROTEM can run four. The TEG initiates coagulation with
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kaolin or a combination of tissue factor and kaolin (± heparinase), and in the ROTEM there are
multiple reagent options that may help to distinguish between the causes for abnormal traces,
described in table 3 [8, 9]. Relevant to measuring fibrinolysis, one of these (APTEM) contains
the fibrinolytic inhibitor aprotinin; correction of an abnormal trace by adding this reagent has
been used to suggest the presence of hyperfibrinolysis. It is important to note also that reference
ranges vary considerably between the two technologies, and hence results are not directly
comparable between the instruments [80].
A major advantage of the thromboelastogram and one that has lead to its principle uses during
major surgery, is that it can be used as a bedside measure of global haemostasis, the graphical
output appearing as a real-time representation of the patient’s clot formation and lysis over a
20-30 minute assay time, avoiding delays inherent in sending samples for laboratory analysis.
Furthermore, non-anticoagulated whole blood can be used, and therefore many of the
interactions between coagulation, platelets and fibrinolytic factors are preserved. A limitation
is that the coagulation is being measured under static (no shear) conditions in a plastic cuvette
rather than an endothelialised blood vessel [9], although of course this disadvantage is shared
with almost all other in vitro assays.
TEG Parameter ROTEM Parameter Description Proposed measured variables
R (Reaction) CT Clot Time – period to 2mmamplitude
Coagulation factors, platelets,
anticoagulants
K CFT Clot Formation Time – periodbetween 2 – 20mm amplitude
Coagulation factors, fibrinogen,
platelets
α - angle α - angle Rate of clot formation – slope oftrace
Coagulation factors, fibrinogen,
platelets
MA MCF Maximum amplitude – maximumclot firmness on trace
Fibrinogen, platelets,
fibrinolysis
G MCE
Shear elastic modulus strength or
clot elasticity – a representation of
clot strength
Platelet function, fibrinogen
LY30, LY60 LI 30 Percent decrease in amplitude 30 or60 minutes after MA is reached Fibrinolytic factors, fibrinogen
EPL -
Estimated Percentage Lysis - rate of
change of amplitude after MA is
reached
Fibrinolytic factors, fibrinogen
- ML Maximum Lysis at the end ofROTEM test (20 - 40 mins) Fibrinolytic factors, fibrinogen
Table 2. TEG and ROTEM nomenclature for measured parameters [8, 9, 77]
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A concern with thromboelastography has been in the standardisation of methods and
reproducibility of results. Pre-analytical variables such as site of blood sampling, time from
sampling to analysis, type of reagent and instrument used can alter results significantly
[reviewed in 8]. In addition to native whole blood, re-calcified citrate samples may be used
when thromboelastography is performed in the haemostasis laboratory, or when a delay
 
Figure 1. (a) Normal TEG trace. The patient’s thromboelastographic trace is shown in white and is produced in real
time. The x-axis is time; the y-axis is millimetres of deviation representing increasing visco-elasticity of the sample as
clot forms. Derived parameters are listed below the trace with their proposed normal ranges. R = Clot time; K = Clot
formation time; Angle deg = α – angle or Rate of Clot formation; MA = Maximal Amplitude; G = Shear elastic modulus
strength; LY30/60 = Percent Lysis at 30/60 minutes; CL30/60 = Inverse of LY30/60 parameter; EPL = Estimated Per‐
centage Lysis; (b) TEG trace showing hyperfibrinolysis. The patient’s trace in white shows early convergence repre‐
senting a reduction in visco-elasticity caused by complete fibrinolysis. The key to the derived parameters displayed
below the trace is given in Figure 1a above
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between sampling and analysis is expected in a POC setting. However it has been reported
that stable results are not produced until after 30 minutes of collection in citrate, which defeats
the purpose of the technique as a ‘real-time’ assessment of haemostasis, and values from citrate
samples cannot be correlated to those from non-anticoagulated samples [81].
Operating the TEG or ROTEM in a POC setting means that non-laboratory staff must run these
moderately complex tests and hence sufficient numbers need to be properly trained to operate
and maintain the equipment to avoid further errors. Quality assessment (QA) must be carried
out on a regular basis, the TEG for example requiring quality control (QC) samples to be run
each time the machine is switched on, every 8 hours or if the analyser moved [10]. Commercial
samples for internal quality control are available and external QA schemes exist, but the results
from the latter have been disappointing [82]. Coefficient of variation (CV) results between
centres have been reported between 7.6 – 39.9% in the TEG and 3.6 - 83.6% in the ROTEM [82,
83] for coagulation variables on plasma samples, although much better results in both devices
can be produced in a single centre using whole blood if the manufacturer’s method is followed
exactly [9, 84].
No data on the reproducibility on fibrinolytic measures between centres has been published.
The effect of fibrinolysis on TEG or ROTEM instruments can be detected using the parameters
that are listed in Table 2. However, operators can also use a qualitative difference in the shape
of the traces to diagnose hyperfibrinolysis, an example of which is shown in Figure 1b.
Although subjective, experienced operators have used this strategy successfully in complex
surgery to guide treatment of hyperfibrinolysis as described below, and the effect of giving an
anti-fibrinolytic agent in vivo or adding aprotinin in vitro in the APTEM is clearly demonstrated
in the traces of these patients [77, 78, 85-87]. However, the validity and sensitivity of this
approach is unclear and in some reviews it has been suggested that only marked hyperfibri‐
nolysis can be identified this way [33, 88]. Some investigators using the TEG have attempted
Assay Reagents Proposed Use
TEG
Kaolin Kaolin Overall coagulation assessment
Rapid TEG Kaolin + Tissue Factor Shorter test time / faster results
Heparinase Kaolin + Heparinase Detection of heparin
ROTEM
In-TEM Contact activator Assessment of intrinsic pathway
Ex-TEM Tissue Factor Assessment of extrinsic pathway
Hep-TEM Contact activator + Heparinase Detection of heparin
Ap-TEM Tissue Factor + Aprotinin Detection of fibrinolytic effect when used with EX-TEM
Fib-TEM Tissue Factor + Platelet antagonist Qualitative assessment of fibrinogen
Table 3. Selected TEG and ROTEM reagents [9]
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to standardise the definition of hypofibrinolysis as an ‘Estimated Percent Lysis’ (EPL) of
greater than 15% [88]; this is calculated by the TEG software comparing the area under the
curve at the MA amplitude and 30 minutes later. Validation of this definition as a measure of
hyperfibrinolysis is lacking, but a recent publication has shown that increasing concentrations
of tPA at pathophysiological levels added in vitro lead to higher EPL levels in a dose dependent
way (but not in the less sensitive RapidTEG) [89]. Also, important clinical correlations with
outcome have been found with this EPL threshold (see the studies reviewed below). In the
ROTEM there is some data to suggest the maximum lysis measure at 1 hour correlates with
tPA, PAPs and PAI-1 [79], and the clot lysis index at 30 mins has 71% sensitivity for hyperfi‐
brinolysis when compared to the less quantitative euglobulin clot lysis test (described in a later
section) [78].
In discussing the literature regarding the use of thromboelastography as an assay of fibrinol‐
ysis, first the established uses as a POC device in surgery and trauma will be summarised,
although detection of hyperfibrinolysis in these situations is only a component of the data
utilised. Following this, the research concerning the use of the technique in pregnancy,
haemophilia and hypercoagulable states will be discussed.
Hepatic surgery
One of the first clinical applications described was in orthotopic liver transplantation where
the TEG can be used to monitor coagulation and guide blood component and anti-fibrinolytic
therapy [90]. The haemostatic defect in these patients is complex; they often start with a
thrombocytopenia and depletion of clotting factors due to end stage liver disease, but also
have low levels of the natural anticoagulant proteins C, S and antithrombin. During surgery
they may have a rapidly changing picture due to consumption of factors and dilution. Patients
may also develop hyperfibrinolysis caused by tPA build up during the anhepatic stage,
followed by a surge of tPA release from the reperfused transplant liver [91, 92]. However,
unnecessary use of anti-fibrinolytics should be avoided due to the risk of hepatic artery
thrombosis. POC thromboelastography can produce timely information at intervals through‐
out the surgery on the nature of the defect and requirements for coagulation factor replacement
or anti-fibrinolytic therapy, and has been shown to decrease the need for red cell transfusion
and plasma products [90, 93-95].
Cardiac surgery
Cardiac surgery requiring cardiopulmonary bypass is a complex balance between anticoagu‐
lation with heparin, the effect of anti-platelet agents and the need for haemostasis at the end
of surgery [10]. Hyperfibrinolysis may also be seen, particularly post-bypass. There is good
evidence from randomised controlled trials and retrospective analysis that the use of throm‐
boelastography-guided algorithms for heparin reversal, blood component and anti-fibrino‐
lytic support reduce the need for blood product transfusion and the rates of surgical re-
exploration due to post-operative bleeding [96-100]. For example, a randomised prospective
trial of 105 patients undergoing complex cardiac surgery compared TEG-guided transfusion
therapy with standard care and found significantly fewer transfusions in the TEG group due
to less postoperative requirements [97]. This trial also showed a 75% drop in the number of
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patients having FFP infusion and a 50% fall in platelet transfusion. Because the use of TEG and
ROTEM has been shown to reduce the potential risk to the patient and to reduce costs [96,
101], their use has been recommended in both US and European guidelines [102, 103].
Trauma
Increased understanding of trauma associated coagulopathy has shown that fibrinolysis is a
key component which is associated with increased mortality and can be reliably detected by
thromboelastography in the emergency department, combat settings and operating theatres
[for recent reviews see 10, 33]. Interest in this area has grown further since the publication of
the large multi-centre CRASH-2 study which showed decreased mortality if trauma patients
were given tranexamic acid to inhibit fibrinolysis within three hours [11]. However the
inclusion criteria were very broad in this study, and POC testing with TEG may be able to
target anti-fibrinolytic therapy to those who would benefit most. For example, a recently
published prospective study used TEG to evaluate a severely injured cohort of patients for
hyperfibrinolysis, defined as an EPL of 15% or more [104]. The incidence was 11% overall, but
these patients had 25 times the risk of early mortality. The TEG assay was reported to rapidly
identify hyperfibrinolysis within the first hour in all patients, allowing potential early use of
anti-fibrinolytics. The results replicate a smaller study using the ROTEM [105]. These devel‐
opments warrant further prospective randomised trials to demonstrate a reduced morbidity
or survival benefit in trauma patients monitored by thromboelastography and treated
accordingly.
Haemophilia
Little has been published on the use of thromboelastography in inherited bleeding disorders.
However, the TEG has been used to demonstrate hyperfibrinolysis in Haemophilia A, and this
was correctable with either recombinant FVIIa or an anti-fibrinolytic or both [86, 106], and the
TEG is also able to monitor the effect of rFVIIa used to treat haemophilia patients with acquired
inhibitors [107].
Hypercoagulable or hypofibrinolytic states
Thromboelastography has been less successful in demonstrating hypofibrinolysis. This may
be because normal subjects only show a minor degree of fibrinolysis in unmodified TEG or
ROTEM assays, for example one study showing the normal range of the ROTEM Maximum
Lysis at 60 minutes to be 0 – 12% (mean 3%) [84]. Modifications have been suggested to increase
the sensitivity to hypofibrinolysis by adding exogenous tPA to the cuvette prior to clot
initiation, but there has been little published on the success of this approach; one group
described a standard method for measuring tPA induced fibrinolysis using the TEG and
subsequently used it to show that children with idiopathic venous thrombosis have signifi‐
cantly reduced fibrinolysis compared to controls [108, 109]. The data concerning the use of
thromboelastography in hypercoagulable states has otherwise concentrated on the ability of
the technique to show shortened clotting times, rapid fibrin polymerisation or increased clot
strength [e.g. 110], and is outside the scope of this chapter.
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Pregnancy
Pregnancy is a hypercoagulable state in which many of the component s of the coagulation
and fibrinolytic system are altered, but conventional assays fail to provide an overall picture
of the patient’s haemostatic potential. Thromboelastography has been used in this regard, and
has been successful in guiding therapeutic anticoagulation with LMWH and assessing the risk
of neuraxial anaesthesia [reviewed in 8, 10]. A minor degree of hypofibrinolysis can be detected
by TEG at the end of the third trimester compared to 8 weeks post partum [111], and an
algorithm for TEG-guided treatment of post partum haemorrhage has been suggested, similar
to those used in trauma [112].
Conclusion
Thromboelastography has an established clinical role in the detection of hyperfibrinolysis in
major hepatic and cardiac surgery, and its use in the management of trauma victims is growing.
As further awareness and understanding of the assay occurs, further applications in bleeding
patients [112], haemophilia and pregnancy are likely [113]. However, an expansion of its role
into detection of hypofibrinolysis is unlikely given the insensitivity of current methodologies.
4. Fibrin generation and lysis assays
Attempts had been made to time the dissolution of plasma clots as an overall measure of
fibrinolysis even before the development of molecular markers and their immunoassays.
However, spontaneous fibrinolysis of plasma clots is an extremely slow process, for example
taking as long as 20 hours to achieve just 10% lysis [114]. Laboratory assays were subsequently
developed that could measure fibrinolysis over a shorter period, principally the euglobulin
clot lysis time (ECLT) [115] and the dilute whole blood clot lysis time (DWBCLT) [116].
However they have not been widely adopted because of several drawbacks. The ECLT
measures lysis in only a fraction of plasma precipitated by utilising a low pH and ionic strength;
the main determinants are fibrinogen, tPA and plasminogen only, the natural inhibitors being
absent. DWBCLT is performed in the absence of calcium and hence excludes the interplay of
the coagulation and fibrinolytic systems, and both of these tests were also labour intensive and
unsuited to modern clinical laboratories.
4.1. Clot lysis time (CLT)
More recently an automated assay called the clot lysis time (CLT) has been developed to assess
the dissolution of a tissue factor induced fibrin clot by exogenous tPA [117]. Citrated platelet-
poor plasma (PPP) is added to a microtitre plate at 37oC with tissue factor, calcium, phospho‐
lipid to initiate clot formation and exogenous tPA to trigger fibrinolysis. The turbidity at 405nm
is measured over time. The CLT is defined as the time from the midpoint of clot formation
(between clear and maximum turbidity) to the midpoint of clot lysis (between maximum
turbidity and clear). It has a mean (± SD) in normal individuals of 83.8 (± 11.1) minutes [118].
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The CLT has several advantages. Firstly, it is relatively simple and easy to run. It can be done
on previously frozen samples and is insensitive to method of PPP preparation [118]. It provides
an assessment of the overall fibrinolytic capacity of the plasma, being affected by most of the
individual factors. Plasminogen, α2-plasmin inhibitor, PAI-1 and TAFI all have been shown
to be important variables in the CLT, whilst prothrombin, fibrinogen and factors VII, X and XI
have a progressively more minor effect [27]. However, the concentration of the exogenous tPA
is above physiological levels, and important interactions with platelets are not accounted for.
The CLT has been poorly standardised between groups, but a recent publication has sought
to address this and investigate the biological variation within healthy individuals [118]. It was
identified that the assay has a total analytical CV of 13.4%, and there is substantial biological
variance over time within normal individuals. Sequential samples are therefore required to
establish the true fibrinolytic potential of an individual; the authors suggest a single result may
differentiate up to 20% from the true value. These should be done at the same time of day
because the assay is affected by the diurnal variation in fibrinolysis that was previously noted
in plasma levels of tPA and PAI-1, but no seasonal variation was detected. As it is a turbido‐
metric assay, results may also be affected by marked lipaemia or paraproteinaemia.
Venous thromboembolism
There is definitive evidence that reduced fibrinolytic potential as shown by prolonged CLT is
a risk factor for first venous thromboembolism (VTE). The LETS case control study determined
the CLTs for 421 patients following their first DVT selected consecutively from anticoagulation
clinics and excluded only if aged over 70 or if they had a malignancy [117]. Samples were taken
at least 6 months after the diagnosis and at least 3 months after the cessation of anticoagulant
and were matched with 469 control samples from patient’s partners. A dose-dependent
correlation was seen between increased CLT and DVT, with those with CLTs above the 90th
percentile having twice the risk of controls, even when corrected for age, sex, clotting factors,
antithrombin and TAFI levels. A second smaller study investigated lysis times in a group of
100 patients with a first idiopathic VTE using a similar turbidometric assay [119]. Patients were
excluded if they had any known congenital or acquired risk factors for thrombosis or evidence
of an underlying inflammatory state; the included VTE patients showed mean clot lysis times
that were a 31.9% longer than controls. Findings were replicated in the Multiple Environmental
and Genetic Assessment (MEGA) study of 2090 patients with first DVT or PE and 2564 controls
[120]. Patients were between 18-70 years and were excluded if death or end-stage disease
prevented follow-up samples being taken, whilst the control group was comprised of the
patient’s partners and random healthy individuals. Again, a dose dependent increase in risk
of DVT was seen for increasing CLTs. The authors defined hypofibrinolysis as those with a
CLT above the 75th percentile, and these patients had a two-fold risk compared to those in the
first quartile. Interestingly, a synergistic effect was seen when CLT was combined with other
known risk factors. Immobilisation increased the risk of VTE 4.3-fold in this study, but
combined with hypofibrinolysis the risk was over 10 times that of controls. The overall risk
with Factor V Leiden heterozygosity increased from 3.5 to 8.1-fold but the combination with
prothrombin 20210A mutation did not show the same effect. Most markedly, for women under
50 years on the oral contraceptive, the risk of first VTE went up from 2.6-fold to over 20-times
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the risk if they also had hypofibrinolysis. Previously it had been shown that OCP use had either
a minor [121] or no effect [122, 123] on prolonging the clot lysis time by itself.
Recurrent VTE
The establishment of hypofibrinolysis defined by CLT as a risk factor for first VTE has led to
interest in whether it could predict recurrent events, and therefore be used in clinical decision-
making on the duration of anti-coagulation in patients. The LETS population was prospec‐
tively studied to see if prolonged CLTs detected after the first DVT predicted recurrent VTE
[58]. In a group of 447 patients with a mean follow-up of 7.3 years, no significant association
was seen in the 90 patients with recurrence. In a second study, 704 patients with a first
unprovoked VTE and no genetic risk factor, malignancy, lupus anticoagulant or other
requirement for long-term anti-coagulation, were studied [124]. In the female population
(n=378), there was a 3.28-fold risk of recurrence for those with a CLT in the fourth quartile, but
no association with recurrence was found in men or the overall population. Whilst these results
are disappointing, there may be reasons why some effect was not detected; it should be noted
that in the LETS study, patients with temporary risk factors such as immobility were included
in the study although they had a low risk of recurrence, and in both studies patients who
remained on anti-coagulation for any reason were excluded, including those continuing
because they were thought to be high risk for recurrence. In neither of these studies were CLTs
combined with other known predictors of recurrence, such as elevated D-dimer or Factor VIII
levels, to see if their predictive power could be increased.
Uncommon thrombotic disorders
Some recent interesting research suggests using global methods such as the CLT may provide
insight into the pathogenesis of some poorly understood hypercoagulable diseases. For
example, CLTs were significantly longer (p=0.001) in 81 patients with retinal vein occlusion
compared to a matched control group, even when multivariate analysis adjusted for cardio‐
vascular risk factors [125]. Another study showed CLTs above the 95th percentile gave a 3.4-
fold increase risk of Budd-Chiari syndrome [28], and 92 patients with pre-eclampsia were
found to have significantly prolonged clot lysis times compared to controls, independent of
the presence of antiphospholipid antibodies [126].
Arterial thrombosis
Clot lysis times have also been studied as a risk factor for arterial disease in 3 recent studies.
The first used samples from the large case control study population from the Study of
Myocardial Infarction Leiden (SMILE) to test CLT in 421 men and 642 controls [127]. Samples
in the study group were taken a median 2.6 years after first MI. In men under 50 years the
overall risk of MI was 3.2 times (95% CI 1.5-6.7) increased for CLTs in the highest quartile;
however, once cardiovascular risk factors were adjusted for the risk was attenuated to just 1.8
(95% CI 0.7-4.8), and no relationship was seen in the over 50s. Another case-control study (from
the ‘ATTAC’ study) examined the association between CLTs and ischaemic stroke, peripheral
vascular disease as well as MI in both sexes [123]. Even after adjusting for cardiovascular risk
factors there was an approximately 2-fold increase in risk of arterial event associated with CLTs
above the 80th percentile (compared to the risk associated with diabetes which was 2.5), and
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the association was similar in the 3 categories of disease. Finally, a third case-control group
(the RATIO study) found a significant association between CLT and arterial thrombosis in
young women aged 18-50 [128]. The risk of MI was increased for those with CLT in the third
tertile, but surprisingly the risk of ischaemic stroke was only increased by shortened CLTs, i.e.
with hyperfibrinolysis, a finding which is yet to be validated or explained.
Anticoagulants and hypocoagulable states
Given the evidence that some patients with thrombosis have impaired fibrinolysis, one
interesting area of investigation concerns the effect of different anticoagulants on fibrinolysis
measured by the CLT. Data on their effect could help to interpret CLT studies on patients with
VTE without the need to take them off their anticoagulation, which was a methodological
problem in the studies on recurrent VTE risk described above. Another possible benefit might
be the ability to individualise anticoagulant choices for patients with hypofibrinolysis. Three
studies have addressed the effect of anticoagulants. CLTs were measured in an in-vitro study
where varying concentrations of anticoagulants including a low molecular weight heparin
(LMWH), a selective anti-Xa drug (fondaparinux) and thrombin inhibitors (hirudin and
PPACK) [129]. The LMWH and fondaparinux both had a significant effect in shortening CLTs,
whereas no effect was seen with the thrombin inhibitors. A second study looked at the in-vivo
use of unfractionated heparin (UFH) and LMWH in the treatment of acute PE, and found that
fibrinolysis was enhanced significantly in the UFH group versus those on LMWH [130]. A
third study showed that fondaparinux shortened CLTs in vitro and in healthy subjects, and
this could be partially reversed with rFVIIa [131].
There has been comparatively little research on the utility of CLT in measuring hypocoagulable
or hyperfibrinolytic conditions. In haemophilia A, hyperfibrinolysis has been demonstrated
by shortened CLTs, and can be abolished by adding FVIII, TAFI or recombinant activated
Factor VII (rFVIIa) [132, 133]. Another study used shortened CLTs to demonstrate hyperfibri‐
nolysis in liver cirrhosis [134].
4.2. Overall Haemostatic Potential (OHP)
A limitation of the CLT is that only a single timed variable representing fibrin degradation is
produced from the process of fibrin generation and subsequent lysis. A more comprehensive
method for investigating this process is provided by the Overall Haemostatic Potential assay
which was first developed in Sweden by Blombäck and colleagues [135] and modified in
subsequent publications [136-138]. The principle of the OHP is the generation of fibrin
formation and lysis curves to represent the shifting balance between fibrin generation and lysis
using serial spectrophotometric measurements plotted against time. Two other assays with
very similar methods have been described and will be also considered in this section. These
are the Clot Formation and Lysis (CloFAL) assay [139] and the Coagulation Inhibitor Potential (CIP)
assay [140, 141].
The modified OHP [136, 138] uses a small amount of thrombin to trigger coagulation. Fresh
or thawed citrated PPP is added to a microtitre plate well at 370C containing buffer with calcium
chloride and thrombin at a final concentration of 0.03 – 0.04 IU/ml. Light absorbance at 390 or
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405nm is recorded every minute for 40-60 mins. As the fibrinogen is gradually converted to
fibrin by generated thrombin, the absorbance increases and is recorded at each time point, with
the area under the curve (AUC) reflecting the total fibrin generated. The measurements from
this well are termed the Overall Coagulation Potential (OCP). Each sample is run in parallel
with another well containing the same reagents but with added tPA at 330 – 350ng/mL. In this
analysis, called the Overall Haemostatic Potential (OHP), complete fibrinolysis occurs after
initial fibrin generation, recorded by a fall in absorbance over time. The difference between
the AUCs of the OCP (without tPA) and the OHP (with tPA) represents the overall fibrinolytic
potential (OFP) and is expressed as a percentage of the OCP. Examples of these curves are
shown in Figures 2a and b. Other derived measures include the Delay, which is the time from
start of the analysis to onset of fibrin generation and correlates with the APTT, the maximum
optical density (Max OD) representing the maximal amount of fibrin generated (correlating to
plasma fibrinogen levels), and the velocity (Max Slope) to describe the rate of fibrin generation
[138]. In addition, the OFP may be corrected for variations in Delay by standardising the time
period over which it is calculated to the 45 minutes starting from the onset of fibrin generation
(OFP 45).
Tests are performed in duplicates in a microtitre plate. In a single laboratory the intra-assay
CVs were approximately 3.1 – 8.7% and the inter-assay CVs 4.2 – 5.1% for the OCP and OHP
values respectively [136]. Experiments in our laboratory have shown that standard precautions
may be applied regarding pre-analytical variables; fresh samples are stable if processed within
2 hours or may be frozen and analysed later, and different methods of PPP preparation did
not alter assay results either (unpublished data).
The OHP has demonstrated sensitivity to changes in both coagulation and fibrinolytic factors.
In vitro experiments using factor deficient plasma have demonstrated significant correlations
between OHP parameters and concentrations of factors II, V, VII, VIII, IX and X and XI [142].
These results were replicated in our laboratory, and we also have shown using in-vitro
experiments that the OFP parameter is sensitive to varying concentrations of plasminogen,
α2-plasmin inhibitor, PAI-1, TAFI and the fibrinolytic inhibitor tranexamic acid [unpublished
data and 143]. In vitro spiking experiments have shown fibrinogen concentration outside the
normal range also has a negative correlation with fibrinolysis parameters; however, whereas
fibrinogen levels can have a marked effect on the CLT assay because of the increase in the clot’s
peak light absorbance, the nature of the OFP parameter as a ratio of the OCP-OHP:OCP
controls for the maximum OD and is a reasonable expression of clot lysis.
The OHP can also be used as a screening assay for heritable thrombophilias; previously
unpublished evidence from our laboratory shows sensitivity to antithrombin deficiency with
both hypercoagulable and hypofibrinolytic changes (figure 3), the latter defect likely related
to increased TAFIa levels. The Coagulation Inhibitor Potential (CIP) assay is a newer modification
of the OHP specifically designed for thrombophilia screening which uses heparin pentasac‐
charride to potentiate antithrombin and the snake venom Protac to activate Protein C [140,
141]. It has shown excellent sensitivity of 100% and reasonable specificity of 70-80% in two
small series of patients with FV Leiden, or Protein C, S or antithrombin deficiency [140, 144].
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Whilst there are clear advantages of the OHP as an assay for fibrinolysis, such as its simplicity,
inexpensiveness and reproducibility, there have been several criticisms of the method [145].
The first is that thrombin is used to initiate coagulation. In earlier versions of the assay, higher
thrombin concentrations were used and there was evidence of direct fibrinogen activation
 
Figure 2. (a) Examples of Overall Coagulation Potential (OCP) and Overall Haemostatic Potential (OHP) curves. (b) The
Overall Fibrinolytic Potential (OFP) is the difference of the area under the curves of the Overall Coagulation Potential
(OCP) and Overall Haemostatic Potential (OHP)
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occurring from the exogenous thrombin. However the very low concentrations used in the
modified version produce no detectable clot in thrombin deficient plasma, suggesting the
exogenous thrombin is only enough to trigger coagulation via a feedback reaction and not
directly converting fibrinogen [145]. Even so, a further refinement of the method has been
published which replaces the thrombin with a low concentration of tissue factor and phos‐
pholipid to more accurately mirror in-vivo coagulation and this method has also been shown
to be sensitive to changes in coagulation factor and PAI-1 concentrations [137]. The CloFAL
assay has also been independently developed with a very similar method to the OHP using
tissue factor as an initiator, and a different algorithm to evaluate fibrinolysis [139].
A second criticism of the OHP is that plasminogen activation depends almost exclusively on
the exogenous tPA, a modification of the method which is essential to produce measurable
Figure 3. Overall Haemostatic Potential (OHP) curves of a patient with congenital antithrombin deficiency before and
after antithrombin concentrate infusion compared to a pooled normal plasma control. The pre-infusion OHP curves
show decreased Delay, increased Max Slope and Max OD, and impaired fibrinolysis. Delay, Max Slope and fibrinolysis
are partially corrected by antithrombin infusion.
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fibrinolysis within a reasonable time frame but which makes the assay insensitive to changes
in endogenous plasminogen activators [145]. Thirdly, the effects of the cellular components
are excluded by the use of PPP, unlike in the TEG for example. Finally, the OHP and related
assays currently lack standardisation and are not available commercially, and variations in
type of initiator, concentrations of reagents and derived parameters making results between
groups difficult to compare. As yet, no inter-laboratory CVs have been published. OFP results
are also likely to show a diurnal variation due to their sensitivity to higher PAI-1 levels in the
morning, and this has been demonstrated in patients with obstructive sleep apnoea [146].
Arterial thrombosis
Impaired fibrinolysis demonstrated by the OHP assay has been found in patients with
coronary heart disease. A large retrospective study compared 800 patients three months after
their first MI with 1123 normal controls from the local population [147]. Fibrinolytic parameters
below the 10th percentile of the control group’s values conferred an odds ratio of first MI of 1.66
(95% CI 1.22-2.27) after correction for cardiovascular risk factors in multivariate analysis. In
another study, serial samples from patients admitted to hospital with acute coronary syndrome
showed decreased fibrinolysis that improved on treatment with LMWH [148]. Patients with
stable coronary artery disease also have reduced fibrinolysis; 56 patients with angiography
proven coronary atherosclerosis had significantly reduced OFP values compared to controls
[149]. The lowest tertile of OFP results conferred an odds ratio of 16.1 for coronary artery
disease compared to the highest tertile. This major increase in risk was partly accounted for
by higher PAI-1 levels although the global OFP measure remained an independent risk factor
when adjusted for this.
The OHP has also demonstrated hypofibrinolysis in patients with cerebrovascular events. In
one study, samples were taken from a group of 44 young patients a median of 5 years after
they had experienced an episode of acute cerebral ischaemia and compared to healthy age
matched controls. Little difference in the incidence of traditional thrombophilic measures was
seen between the groups, but increased OCP parameters and decreased OFP results were
demonstrated [150]. Another study examined TAFI levels and the OHP in patients at the time
of acute ischaemic stroke and 60 days later [151]. Patients had impaired global fibrinolysis
compared to controls which was partly, but not fully, explained by raised TAFI levels.
Venous thrombosis
Currently there is less published evidence regarding the use of the OHP to detect hypofibri‐
nolysis in patients with venous thrombosis, although the assay does show promise in this area.
The Swedish group first published data on a group of 88 women who had had a pregnancy
related VTE, with the majority having evidence of activated protein C resistance with or
without the Factor V Leiden mutation [152]. Blood samples were taken for OHP analysis from
the patients 8 months to 13 years after the last VTE and compared to samples from a control
group of healthy women. They were able to demonstrate a significant persisting hypercoa‐
gulability and hypofibrinolysis in the group which was most marked in those who had Factor
V Leiden. Subsequently another publication studied 161 patients referred to haematology
clinic with clinically defined hypercoagulable states [138]. The study group was heterogenous
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and included patients with VTE (n=73), arterial thrombi, antiphospholipid antibodies or lupus
anticoagulant, and pregnancy complications. Despite this, significant differences in fibrin
generation and lysis were found in the study population compared to a control group of blood
donors, giving the OHP assay an estimated sensitivity of 96% for detection of clinically defined
hypercoagulable states. The results of this study complement the excellent sensitivity the OHP
has demonstrated in detecting inherited thrombophilic states that was described previously
[140], and data showing that the OHP can discriminate factor XII deficient patients with a
prothrombotic phenotype [153].
These promising results merit further prospective study to investigate whether the OHP assay
can predict first or recurrent VTE. It may be particularly useful in identifying hypercoagula‐
bility in patients with otherwise unprovoked idiopathic VTE; in our laboratory we have noted
impaired fibrinolysis in this group (unpublished), and similar results have been published
using the CloFAL assay in paediatric VTE [154].
Pregnancy
The OHP assay demonstrates both significantly increased fibrin generation and decreased
hypofibrinolysis in normal pregnancy [J Curnow et al, personal communication, 136]. In high
risk pregnancy, these changes have also been described [155] and unpublished data from our
laboratory shows a significant worsening in these parameters compared to patients with
uncomplicated pregnancy, which may indicate a role for the OHP in prospective studies of
thrombosis risk.
Anticoagulation monitoring
The OHP shows potential applications in the monitoring of overall coagulation and fibrinolytic
changes with anticoagulation. As described above, improvement of fibrinolysis was seen in
acute coronary syndrome patients once LMWH was started [148], and similar improvement
may be seen with warfarin and the new oral anticoagulants (unpublished data). However, the
response appears to be variable even when conventional assays show anticoagulation to be
within the therapeutic window; for example, in a study of pregnant women with previous
thromboembolism, dalteparin prophylaxis was shown to improve hypercoagulable OHP
variables in the majority, but some patients were seen to remain hypercoagulable even with
therapeutic anti-Xa results [155]. Further study is required to investigate if this translates to an
increased thrombosis risk and whether changing treatment based on OHP results can result
in improved patient care.
Hypocoagulable states
As mentioned previously, the OHP is sensitive to factor deficiencies in vitro. Results from
Haemophilia A patients indicate the OHP may even be a better predictor of clinical phenotype
than APTT levels or FVIII assays [145], and in patients with inhibitors, the OHP may be used
to monitor the fibrin generation response to recombinant FVIIa treatment [143]. Studies
evaluating the OHP’s ability to monitor FVIII dosing are ongoing [145].
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Summary
Fibrin generation and lysis assays show sensitivity to both hypo- and hyperfibrinolytic states,
unlike the thromboelastography. Although they have not entered clinical practice currently,
they show great promise in identifying global changes in coagulation and fibrinolytic tenden‐
cy. In this regard, the OHP has an advantage over the CLT because both aspects of haemostasis
are derived. Clearly, further study is required, but the OHP and related assays have the
potential to better characterise global coagulation responses than conventional assays, possibly
leading to individualised treatment for patients with thrombotic and bleeding conditions.
5. Conclusions
Currently, fibrinolysis is rarely measured in clinical practice. This has been mainly due to the
failure of assays of the specific factors to show consistent relationships with disease. In part,
this failure has been related to methodological flaws in the assays, for example in the variable
specificities of the antibodies used to detect TAFI or PAI-1. However, the principle problem is
that the validity of one-off sampling of individual factors as a representation of the complex
fibrinolytic pathway is questionable, especially when the sampling has occurred at a time
distant to the pathological event being investigated.
D-dimer assays have been one notable success in clinical practice where they have established
applications in the diagnosis of VTE and DIC. However, as a non-specific marker of thrombosis
and fibrinolysis, they provide little information of the fibrinolytic potential of an individual.
Global assays have the ability to improve clinical fibrinolytic testing in this regard. Throm‐
boelastography is increasingly establishing itself as a tool to detect hyperfibrinolysis, particular
in point-of-care settings such as cardiothoracic and liver transplant surgery. Fibrin generation
and lysis assays such as the CLT and OHP have the disadvantage of requiring platelet poor
plasma, but in contrast to thromboelastography, appear to be sensitive to both hyper- and
hypofibrinolysis. Results in studies of arterial and venous thrombosis have been encouraging,
but further research needs to be undertaken to find out whether the data has clinical applica‐
tions, for example in predicting an individual patient’s risk of recurrent thrombosis. In the
meantime, the development of new whole blood tests is ongoing [156, 157], with the hope of
achieving a better simulation of in-vivo fibrinolytic conditions.
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